Reactions 1704, p2 - 2 Jun 2018 PRAC meeting highlights from 14-17 May 2018 Two reviews for ulipristal and daclizumab are now complete, and the PRAC confirms its recommendation for hydroxyethyl starch (HES) solutions for infusion, says the EMA. At its recent May meeting, the PRAC confirmed its previous conclusion about the multiple sclerosis medicine daclizumab (Zinbryta) – that the risks of this medicine (i.e. serious and potentially fatal immune reactions affecting the brain, liver and other organs) outweigh its benefits in patients with multiple sclerosis. The European Commission (EC) withdrew the marketing authorisation for Zinbryta on 27 March this year, following a request from Biogen Idec (i.e. authorisation holder). "However, there are no immediate consequences of the PRAC’s review as Zinbryta is no longer authorised in the EU", noted the EMA. In addition, the PRAC has completed a review of ulipristal (Esmya) following reports of serious liver injury, and concluded that this medicine "must not be used in women with liver problems and that certain other patients may start new treatment courses provided they have regular liver tests". Also, PRAC has recommended that women who are not eligible for surgery should use more than one course of Esmya. Women who are about to have surgery should continue to use only one course. Finally, the PRAC has confirmed that its previous recommendation – to suspend the marketing authorisations for HES solutions for infusion across the EU – remains valid. This decision came after the EC requested the PRAC to consider whether suspending the marketing authorisations for HES solutions "could result in an unmet medical need", noted the EMA. The agency added that the EC also requested the PRAC to "consider the feasibility and likely effectiveness of additional risk minimisation measures". The PRAC’s recommendation will now be sent to the ** regulatory body, CMDh. , for consideration at its upcoming meeting (28-30 May). * PRAC = Pharmacovigilance Risk Assessment Committee ** CMDh = Co-ordination Group for Mutual Recognition and Decentralised Procedures - Human. European Medicines Agency. Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 14-17 May 2018. Internet Document : 18 May 2018. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/ news_and_events/news/2018/05/ news_detail_002954.jsp&mid=WC0b01ac058004d5c1 0114-9954/18/1704-0001/$14.95 Adis © 2018 Springer International Publishing AG. All rights reserved Reactions 2 Jun 2018 No. 1704
Reactions Weekly – Springer Journals
Published: Jun 2, 2018
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera